ArticleActa pharmacologica Sinica2025
Programmed sequential nanostructural conversion at nano-bio interface for synergistic cancer phototheranostics.
Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy.Journal of functional biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prodrugs usually convert into active compounds within cells via endogenous or external stimuli to improve the diagnostic accuracy and therapeutic efficacy, but this singular release profile often fails to meet the multifunctional needs of cancer therapeutics. In this study we proposed a strategy of "nanostructural conversion at nano-bio interface" and constructed a small-molecule nanoprodrug (APO-S-Cy7-TCF) for multifunctional anti-tumor phototheranostics. Upon exposure to redox biomolecules (ROS/GSH) in tumor microenvironment, the pristine nanostructure of APO-S-Cy7-TCF disassembled, releasing Cy7-TCF-OH and APO that interacted with heat shock proteins to initiate apoptosis. Cy7-TCF-OH could then re-assemble into smaller nanosaucers with enhanced photothermal properties and self-augmented ROS-generating capacity, enabling synergistic phototherapy for tumor ablation. In particular, Cy7-TCF-OH nanosaucers were long retained in residual tumors and could further interact with albumin to form smaller Cy7-TCF-OH@albumin nanocomposites that time-dependently activated near-infrared fluorescence for prognostic assessment. Using these biomolecule-derived elements to program supramolecular sequential structural conversions at nano-bio interface, our study establishes a new way for small-molecule-based multifunctional phototheranostic platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.